CoChat

ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of adrenal insufficiency

Open access
Arlt, Wiebke, Baldeweg, Stephanie E, Pearce, Simon H S, Simpson, Helen L · 2020 · European Journal of Endocrinology

The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index, and 1 are not checked yet; 6 of the 31 sources its claims cite were checked for support.

Abstract

We provide guidance on prevention of adrenal crisis during the global COVID-19 crisis, a time with frequently restricted access to the usual level of healthcare. Patients with adrenal insufficiency are at an increased risk of infection, which may be complicated by developing an adrenal crisis; however, there is currently no evidence that adrenal insufficiency patients are more likely to develop a severe course of disease. We highlight the need for education (sick day rules, stringent social distancing rules), equipment (sufficient glucocorticoid supplies, steroid emergency self-injection kit) and empowerment (steroid emergency card, COVID-19 guidelines) to prevent adrenal crises. In patients with adrenal insufficiency developing an acute COVID-19 infection, which frequently presents with continuous high fever, we suggest oral stress dose cover with 20 mg hydrocortisone every 6 h. We also comment on suggested dosing for patients who usually take modified release hydrocortisone or prednisolone. In patients with adrenal insufficiency showing clinical deterioration during an acute COVID-19 infection, we advise immediate (self-)injection of 100 mg hydrocortisone intramuscularly, followed by continuous i.v. infusion of 200 mg hydrocortisone per 24 h, or until this can be established, and administration of 50 mg hydrocortisone every 6 h. We also advise on doses for infants and children.

Verified 2026-10-07 · 1 reference not checked yet

Overview

CoChat Summary

TL;DR

This guidance advises prevention and management of adrenal crisis in patients with adrenal insufficiency during COVID-19, emphasizing education, equipment, empowerment, and stress-dose hydrocortisone regimens. It states patients with adrenal insufficiency are at increased risk of infection and adrenal crisis, but there is no evidence they are more likely to have severe COVID-19, and recommendations are rapid expert consensus rather than systematic review.

Key findings

  • Patients with adrenal insufficiency are at increased risk of COVID-19 and of complications from a triggered adrenal crisis, but there is currently no evidence of a higher likelihood of severe disease course in those falling ill with COVID-19.
  • Prevention uses a 3E framework: Educate on sick day rules and stringent social distancing; Equip with sufficient glucocorticoid supplies and an up-to-date hydrocortisone emergency self-injection kit; Empower with a steroid emergency card or equivalent written instructions.
  • For suspected or confirmed COVID-19 at home, adults and adolescents should take 20 mg hydrocortisone orally every 6 h; children should have their usual daily dose trebled in four equal doses every 6 h; patients on modified-release hydrocortisone should switch to immediate-release hydrocortisone; patients on 5–15 mg prednisolone daily should take 10 mg every 12 h, and those on >15 mg should continue their usual dose split into two equal doses of at least 10 mg each.
  • For clinical deterioration, immediate 100 mg hydrocortisone i.m. is advised in adults and adolescents (25 mg in infants, 50 mg in school children), followed in hospital by 100 mg i.v. hydrocortisone and continuous i.v. infusion of 200 mg/24 h, or 50 mg every 6 h; infants and children should receive initial parenteral 50 mg/m² hydrocortisone followed by 50 mg/24 h in infants and 100 mg/24 h in children.

Methods

  • Design: commissioned urgent clinical guidance document developed by rapid expert consensus, not an extensive systematic review or meta-analysis.
  • Data or sample: no new clinical trial or patient cohort; guidance draws on published guidelines and studies, including a three-compartment model of oral hydrocortisone delivery and the Prevention of Adrenal Crisis in Stress (PACS) study, which included ten otherwise healthy, unstressed adult patients with adrenal insufficiency.
  • Main analysis: expert consensus recommendations, supported by pharmacokinetic modelling of oral hydrocortisone delivery and serum cortisol responses to different stress-dose hydrocortisone administration modes.

Limitations

  • Stated: the document is not based on extensive systematic review or meta-analysis but on rapid expert consensus; it is guidance only and not intended to determine an absolute standard of medical care, with individual circumstances to be considered.
  • Stated: there is currently no evidence that adrenal insufficiency patients are more likely to develop a severe course of COVID-19.
  • Evident: COVID-specific stress-dose recommendations rely on modelling, the authors’ personal experience, and indirect data rather than clinical outcome trials in patients with adrenal insufficiency and COVID-19.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1530/eje-20-0361

Cites

28 of 29 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Steroid emergency card for patients with adrenal insufficiency issued by the UK National Health Service in March 2020 (downloadable at https://www.endocrinology.org/media/3563/new-nhs-emergency-steroid-card.pdf).
Figure 1 Steroid emergency card for patients with adrenal insufficiency issued by the UK National Health Service in March 2020 (downloadable at https://www.endocrinology.org/media/3563/new-nhs-emergency-steroid-card.pdf).CC BY · PubMed Central
Figure 2 Prediction of 24-h oral hydrocortisone delivery dependent on timing and dosing. Prediction based on parameter estimates of circulating cortisol concentrations in a three-compartment model after (A) doubling of immediate release hydrocortisone doses administered at the usual times of two typical routine hydrocortisone regimens (two and three daily doses, respectively) and (B) oral administration of four equal doses in evenly spaced, 6-h intervals. This illustrates that the 6-h once administration ensures steady delivery of cortisol, while increasing hydrocortisone at the usual administration times results in a long stretch of time without appropriate hydrocortisone cover. For details on the employed modelling approach see (19); figure reproduced with permission.
Figure 2 Prediction of 24-h oral hydrocortisone delivery dependent on timing and dosing. Prediction based on parameter estimates of circulating cortisol concentrations in a three-compartment model after (A) doubling of immediate release hydrocortisone doses administered at the usual times of two typical routine hydrocortisone regimens (two and three daily doses, respectively) and (B) oral administration of four equal doses in evenly spaced, 6-h intervals. This illustrates that the 6-h once administration ensures steady delivery of cortisol, while increasing hydrocortisone at the usual administration times results in a long stretch of time without appropriate hydrocortisone cover. For details on the employed modelling approach see (19); figure reproduced with permission.CC BY · PubMed Central
Figure 3 (Panels A, B, C and D) Serum total cortisol (nmol/L) in ten otherwise healthy, unstressed adult patients with adrenal insufficiency who paused their regular replacement and underwent frequent serum sampling after administration of 200 mg hydrocortisone/24 h in four different administration modes: 50 mg orally every 6 h (ORAL), 50 mg per i.m. bolus injection every 6 h (IM), 50 mg per i.v. bolus injection (IVI) and via continuous i.v. hydrocortisone infusion of 200 mg/24 h (CIV). Data are presented as median (black line) and range (shaded grey area). (Panels E and F) Linear pharmacokinetic modelling, based on serum cortisol measurements by tandem mass spectrometry after i.v. IVI and CIV hydrocortisone administration, to predict expected serum cortisol concentrations after 50 mg (E) and 100 mg (F) i.v. bolus injection, each followed by CIV infusion of 200 mg hydrocortisone/24 h. Figure modified after (20); reproduced with permission.
Figure 3 (Panels A, B, C and D) Serum total cortisol (nmol/L) in ten otherwise healthy, unstressed adult patients with adrenal insufficiency who paused their regular replacement and underwent frequent serum sampling after administration of 200 mg hydrocortisone/24 h in four different administration modes: 50 mg orally every 6 h (ORAL), 50 mg per i.m. bolus injection every 6 h (IM), 50 mg per i.v. bolus injection (IVI) and via continuous i.v. hydrocortisone infusion of 200 mg/24 h (CIV). Data are presented as median (black line) and range (shaded grey area). (Panels E and F) Linear pharmacokinetic modelling, based on serum cortisol measurements by tandem mass spectrometry after i.v. IVI and CIV hydrocortisone administration, to predict expected serum cortisol concentrations after 50 mg (E) and 100 mg (F) i.v. bolus injection, each followed by CIV infusion of 200 mg hydrocortisone/24 h. Figure modified after (20); reproduced with permission.CC BY · PubMed Central

Verification

Claims the paper makes

5 Valid · 2 Not valid · 9 Not checked · 3 Own results and interpretations

8 more claims

Create a free account to see all 19 claims and to verify the 25 references still open.

See all claims — free account
  • It may state two separate claims as one. 5
  • Probably not a substantial claim. 3

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 29 references

Cited by

See all 119

Metadata

Authors
Arlt, W., Baldeweg, S. E., Pearce, S. H. S., & Simpson, H. L.
Affiliations
  • University Hospitals Birmingham NHS Foundation Trust (GB)
  • University College London Hospitals NHS Foundation Trust (GB)
  • Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
Corresponding author
Arlt, Wiebke
Venue
European Journal of Endocrinology
Published
2020-07-01
Volume
183
Issue
1
Pages
G25-G32
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W3016271834
Cited by
107
References
28
Citations by year
2026: 1 · 2025: 3 · 2024: 10 · 2023: 14 · 2022: 21 · 2021: 33 · 2020: 25
FWCI
17.44
Type
journal article
Language
en
Open access
Locations
  • European Journal of Endocrinology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Newcastle University ePrints (Newcastle Univesity)
Funders
  • National Institute for Health and Care Research (ICA-CDRF-2018-04-ST2-050)
  • Medical Research Council (MR/J002526/1)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
  • Health Sciences › Medicine › Oncology › COVID-19 and healthcare impacts
Keywords
adrenal insufficiency, adrenal crisis, COVID-19 pandemic, cortisol, stress dose glucocorticoids, sick day rules, infection risk, prednisolone, pediatric adrenal insufficiency, healthcare access restrictions
MeSH terms
Betacoronavirus, COVID-19, SARS-CoV-2, Acute Disease, Adrenal Insufficiency, Adult, Child, Child, Preschool, Endocrinology, Female, Glucocorticoids, Humans, Hydrocortisone, Infant, Male, Pneumonia, Viral, Prednisolone, Steroids, Coronavirus Infections, Disease Management, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of adrenal insufficiency. https://app.cochat.ai/papers/10.1530/eje-20-0361
The paper
Arlt, W., Baldeweg, S. E., Pearce, S. H. S., & Simpson, H. L. (2020). ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of adrenal insufficiency. European Journal of Endocrinology. https://doi.org/10.1530/eje-20-0361

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.